Which statement about IVIG in SJS/TEN reflects a risk listed in the material?

• A. It targets the underlying pathophysiology
• B. Cost
• C. BBW: Thromboembolic event, AKI
• D. Does not increase infection risk

Answer: (C)

IVIG carries important safety warnings that the material highlights, specifically a boxed warning for thromboembolic events and acute kidney injury. This makes the listed risk the best match because it directly reflects the explicit adverse effects associated with IVIG in clinical labeling and practice guidelines. While cost and questions of mechanism are relevant in evaluating IVIG use, they are not the safety risk emphasized here, and saying IVIG does not increase infection risk isn’t the risk focus in the material. The key point is that thromboembolism and AKI are the recognized, reported dangers with IVIG, which is why this statement stands out as the correct reflection of the risk.